Severe Asthma Management
Publication Date: October 1, 2019
Key Points
Key Points
Following the recent appearance of new anti-interleukin biologic agents and standardization of sputum eosinophil counts and exhaled nitric oxide fraction (FENO), ATS/ERS have added recommendations for these agents for adults with severe uncontrolled asthma and modified certain other recommendations from the 2014 guideline.
Treatment
...eatmen...
...commendations for the Management of Severe Asthm...
...an anti-IL-5 strategy as add-on t...
...a blood eosinophil cut-point ≥150 µL−1 can...
...uggest using a blood eosinophil cut-off ≥2...
...a FENO cut-off ≥19.5 ppb to ident...
...ren, adolescents and adults with severe ast...
...a trial of macrolide treatment to reduce asthma...
...gest against the use of chronic mac...
We suggest dupilumab as add-on therapy for...
...e 2. Monoclonal Antibodies for Severe Asth...